SCHEMBL3965353

SCHEMBL3965353

C[C@@H]1CN(CCCN)C[C@H](C)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTR2B P41595 1/20 0.47
HTT P42858 1/20 0.47
SCARB1 Q8WTV0 1/20 0.47
KDM4E B2RXH2 1/20 0.45
KEAP1 Q14145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3718838 0.86 SIGMAR1 (0.42) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL6780999 0.86 SIGMAR1 (0.42) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL3103478 0.80 GLB1 (0.52) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL2384684 0.78 SIGMAR1 (0.47) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL2386357 0.78 SIGMAR1 (0.47) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL10921394 0.78 SIGMAR1 (0.47) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL2387295 0.78 SIGMAR1 (0.47) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL2386353 0.78 SIGMAR1 (0.47) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL2444898 0.78 SIGMAR1 (0.47) SIGMAR1MEN1KMT2AALDH1A1TP53
SCHEMBL3106230 0.78 SIGMAR1 (0.57) SIGMAR1MEN1KMT2AALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG SIGMAR1 3424/4885MEN1 3407/4885KMT2A 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.